Skip to main content
. Author manuscript; available in PMC: 2023 Jan 10.
Published in final edited form as: Nat Med. 2022 Jan 10;28(1):144–153. doi: 10.1038/s41591-021-01600-6

Figure 1|.

Figure 1|

IMbassador250 consort diagram. A total of 759 patients with metastatic castration-resistant prostate cancer who progressed on abiraterone and were ineligible for or declined taxane chemotherapy gave consent and entered the study between June 2017 and May 2018. The number of immunohistochemistry (IHC) and next generation sequencing (NGS) samples of biomarker evaluable population in both arms is shown. FMI: Foundation Medicine.